Enlivex Therapeutics Ltd. has announced that it will present new clinical data from its Phase IIa trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis at the American College of Rheumatology $(ACR)$ Convergence 2025, scheduled for October 24-29 in Chicago, Illinois. The late-breaking poster presentation will feature 3-month topline data from the ENX-CL-05-001 study, reporting clinically meaningful and statistically significant improvements in pain reduction and functional outcomes compared to placebo in idiopathic age-related osteoarthritis patients aged 60 and above. The presentation will also include new biomarker data and findings regarding responder populations. Results will be presented by Professor Philip Conaghan on October 28, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9563395-en) on October 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.